ES2140380T3 - Secuencias de adn que codifican polipeptidos gag retroviricos modificados y vacunas que las contienen o agregados de las mismas. - Google Patents
Secuencias de adn que codifican polipeptidos gag retroviricos modificados y vacunas que las contienen o agregados de las mismas.Info
- Publication number
- ES2140380T3 ES2140380T3 ES91104432T ES91104432T ES2140380T3 ES 2140380 T3 ES2140380 T3 ES 2140380T3 ES 91104432 T ES91104432 T ES 91104432T ES 91104432 T ES91104432 T ES 91104432T ES 2140380 T3 ES2140380 T3 ES 2140380T3
- Authority
- ES
- Spain
- Prior art keywords
- particles
- protease
- gag
- vaccine
- expression
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 229960005486 vaccine Drugs 0.000 title abstract 3
- 108091028043 Nucleic acid sequence Proteins 0.000 title 1
- 229920001184 polypeptide Polymers 0.000 title 1
- 102000004196 processed proteins & peptides Human genes 0.000 title 1
- 108090000765 processed proteins & peptides Proteins 0.000 title 1
- 238000000034 method Methods 0.000 abstract 4
- 239000002245 particle Substances 0.000 abstract 4
- 108091005804 Peptidases Proteins 0.000 abstract 3
- 239000004365 Protease Substances 0.000 abstract 3
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 abstract 3
- 206010046865 Vaccinia virus infection Diseases 0.000 abstract 3
- 241000700605 Viruses Species 0.000 abstract 3
- 208000007089 vaccinia Diseases 0.000 abstract 3
- 239000002243 precursor Substances 0.000 abstract 2
- 102000004169 proteins and genes Human genes 0.000 abstract 2
- 108090000623 proteins and genes Proteins 0.000 abstract 2
- 241000880298 Baculum Species 0.000 abstract 1
- 229940033332 HIV-1 vaccine Drugs 0.000 abstract 1
- 241000725303 Human immunodeficiency virus Species 0.000 abstract 1
- 108010016183 Human immunodeficiency virus 1 p16 protease Proteins 0.000 abstract 1
- 241000713869 Moloney murine leukemia virus Species 0.000 abstract 1
- 238000004458 analytical method Methods 0.000 abstract 1
- 238000010171 animal model Methods 0.000 abstract 1
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 230000015572 biosynthetic process Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000001900 immune effect Effects 0.000 abstract 1
- 230000036039 immunity Effects 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 abstract 1
- 230000035800 maturation Effects 0.000 abstract 1
- 230000002028 premature Effects 0.000 abstract 1
- 230000001681 protective effect Effects 0.000 abstract 1
- 238000004062 sedimentation Methods 0.000 abstract 1
- 238000001228 spectrum Methods 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
- 241000701447 unidentified baculovirus Species 0.000 abstract 1
- 229940125575 vaccine candidate Drugs 0.000 abstract 1
- 238000001262 western blot Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
- C12N2740/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biophysics (AREA)
- Virology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
ESTRATEGIAS DE VACUNAS DEL VIH-1 CONVENCIONALES, BASADAS EN LA PARTE EXTERNA DE LA PROTEINA ENV GP160/120, NO HAN SIDO HASTA AHORA CAPACES DE INDUCIR UNA INMUNIDAD PROTECTORA. ADEMAS, ANTICUERPOS REALZADOS PUEDEN INFLUENCIAR NEGATIVAMENTE LA PROGRESION DE LA ENFERMEDAD. DEBIDO A LA APARICION TEMPRANA EN LA INFECCION Y SU NATURALEZA PARTICULAR, LA PROTEINA P55-GAG DEL NUCLEO DEL VIRUS PARECE SER UN CANDIDATO A VACUNA QUE PROMETE. LA EXPRESION P55-NUCLEO FUE ENSAYADA MEDIANTE UNA COMBINACION DE VACUNA Y VIRUS BACULO. EL VERTIDO DE LAS PARTICULAS DE NUCLEO 90-110 NM EN UN MEDIO DE CULTIVO FUE OBSERVADA EN AMBOS SISTEMAS DE EXPRESIONES Y PROBADOS MEDIANTE UN MICROSCOPIO DE ELECTRON DE SECCION ULTRADELGADA Y ANALISIS DE SEDIMENTACION. LA ADICION DE LA SECUENCIA CODIFICADA DE PROTEASA EN UN PROCESO EFICIENTE DE LA MOLECULA PRECURSORA P55ACULO . PROTEASA SIGNIFICANTE MEDIANTE EL PROCESO DEL PRECURSOR GAG EN EL SISTEMA-VACCINIA QUE SOLO ALCANZADA POR LA ADICION DE LA SECUENCIA CODIFICADA POL ENTERA. EN CONTRASTE CON OTROS RETROVIRUS (MMLV), PROTEASA VIH-1 MEDIATIZADA PROCESADA NO DEPENDE DE LA MIRISTILACION DE P55-GAG. UN PROCESO MEDIATIZADO DE PROTEASA NO COMPLETA EL PROCESO DE MADURACION DE LAS PARTICULAS DE PRECURSOR-P55, PERO EN CONTRASTE, INHIBE LA FORMACION DE PARTICULAS, OTRAS INVESTIGACIONES ENFOCADAS EN LA APLICACION DE PARTICULAS-P55-GAG PREMATURAS. PARA EXTENDER SU ESPECTRO INMUNOLOGICO, UNA SECUENCIA CONSENSUADA DEL MAYOR VIH EPITOPE V3 DE GP120 QUE NEUTRALIZA, DISEÑADO EN NUESTRO LABORATORIO, FUE INSERTADO EN DIFERENTES ZONAS DE LA MOLECULA PORTADORA P55. LA EXPRESION DE LAS PROTEINAS QUIMERICAS P55/V3 EN E. COLI Y EL SISTEMA DE EXPRESION VACCINIA FUE PROBADO POR EL ANALISIS WESTERN BLOT, UTILIZANDO (I) ANTICUERPOS MONOCLONALES DIRIGIDOS A P55 Y LA ZONA V3 INSERTADA Y (II) SERA PEPTIDO MONOESPECIFICO ANTI-V3. PARTICULAS HIBRIDAS P55/V3 SERAN PURIFICADAS DESDE CELULAS INFECTADAS DE BACULOVIRUS. LOS VIRUS DE VACCINIA P55/V3 RECOMBINANTES SON, EN ADICION A LA PRODUCCION DEANTIGENOS, UTILIZADOS DIRECTAMENTE COMO UNA VACUNA VIVA EN ANIMALES EXPERIMENTALES.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP90105319 | 1990-03-21 | ||
EP90105319 | 1990-03-21 |
Publications (2)
Publication Number | Publication Date |
---|---|
ES2140380T3 true ES2140380T3 (es) | 2000-03-01 |
ES2140380T5 ES2140380T5 (es) | 2005-03-16 |
Family
ID=8203785
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES91104432T Expired - Lifetime ES2140380T5 (es) | 1990-03-21 | 1991-03-21 | Secuencias de adn que codifican polipeptidos gag retroviricos modificados y vacunas que las contienen o agregados de las mismas. |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP0449116B2 (es) |
AT (1) | ATE183235T1 (es) |
DE (1) | DE69131513T3 (es) |
ES (1) | ES2140380T5 (es) |
GR (1) | GR3031817T3 (es) |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5773211A (en) * | 1991-07-10 | 1998-06-30 | Abbott Laboratories | Differentiation of HTLV-I and HTLV-II using synthetic peptides |
EP0565794A1 (en) * | 1992-04-14 | 1993-10-20 | British Biotech Pharmaceuticals Limited | Induction of CTL responses |
GB9208218D0 (en) * | 1992-04-14 | 1992-05-27 | British Bio Technology | Hybrid particles |
EP0572737B1 (en) * | 1992-06-04 | 2001-02-28 | The Research Foundation For Microbial Diseases Of Osaka University | HIV Gag-env fusion antigen |
AU6829494A (en) * | 1993-08-02 | 1995-02-28 | Chiron Corporation | Recombinant constructs using replacement sequences in hypervariable regions |
AU744882B2 (en) * | 1997-03-11 | 2002-03-07 | Mayo Foundation For Medical Education And Research | Compositions and methods for elimination of unwanted cells |
EP1141313A2 (en) | 1998-12-31 | 2001-10-10 | Chiron Corporation | Improved expression of hiv polypeptides and production of virus-like particles |
AU2487300A (en) | 1998-12-31 | 2000-07-31 | Chiron Corporation | Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof |
PT1141315E (pt) | 1998-12-31 | 2008-05-05 | Novartis Vaccines & Diagnostic | Polipéptidos do envelope (env) de hiv modificados |
US7935805B1 (en) | 1998-12-31 | 2011-05-03 | Novartis Vaccines & Diagnostics, Inc | Polynucleotides encoding antigenic HIV Type C polypeptides, polypeptides and uses thereof |
EP1311686A2 (en) | 2000-08-14 | 2003-05-21 | THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | Modifications of hiv env, gag, and pol enhance immunogenicity for genetic immunization |
JP5033303B2 (ja) | 2001-07-05 | 2012-09-26 | ノバルティス バクシンズ アンド ダイアグノスティックス,インコーポレーテッド | 抗原性c型hivポリペプチドをコードするポリヌクレオチド、ポリペプチドおよびそれらの使用 |
EP2280074A3 (en) | 2001-07-05 | 2011-06-22 | Novartis Vaccines and Diagnostics, Inc. | Polynucleotides encoding antigenic HIV type B and/or type C polypeptides, polypeptides and uses thereof |
CA2458995C (en) | 2001-08-31 | 2013-04-30 | Chiron Corporation | Polynucleotides encoding antigenic hiv type b polypeptides, polypeptides and uses thereof |
US20030170614A1 (en) | 2001-08-31 | 2003-09-11 | Megede Jan Zur | Polynucleotides encoding antigenic HIV type B polypeptides, polypeptides and uses thereof |
US6835568B2 (en) | 2001-10-30 | 2004-12-28 | Virxsys Corporation | Regulated nucleic acid expression system |
WO2006050394A2 (en) | 2004-11-01 | 2006-05-11 | Novartis Vaccines And Diagnostics Inc. | Combination approaches for generating immune responses |
US8620059B2 (en) | 2007-12-13 | 2013-12-31 | Fpinnovations | Characterizing wood furnish by edge pixelated imaging |
US20140004146A1 (en) * | 2011-03-17 | 2014-01-02 | Institut Pasteur Of Shanghai, Chinese Academy Of Sciences | Method for producing virus-like particle by using drosophila cell and applications thereof |
EP2694101B1 (en) | 2011-04-06 | 2016-09-14 | Biovaxim Limited | Pharmaceutical compositions for preventing and/or treating an hiv disease in humans |
EP3158058B1 (en) | 2014-06-18 | 2019-04-17 | MorphoSys AG | Fusion proteins and uses thereof |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4925784A (en) * | 1986-04-04 | 1990-05-15 | Hoffmann-La Roche Inc. | Expression and purification of an HTLV-III gag/env gene protein |
ES2059823T3 (es) * | 1988-05-06 | 1994-11-16 | Ferropas Ag | Metodos y sistemas para producir antigenos de hiv. |
-
1991
- 1991-03-21 ES ES91104432T patent/ES2140380T5/es not_active Expired - Lifetime
- 1991-03-21 AT AT91104432T patent/ATE183235T1/de not_active IP Right Cessation
- 1991-03-21 DE DE69131513T patent/DE69131513T3/de not_active Expired - Fee Related
- 1991-03-21 EP EP91104432A patent/EP0449116B2/en not_active Expired - Lifetime
-
1999
- 1999-11-10 GR GR990402910T patent/GR3031817T3/el unknown
Also Published As
Publication number | Publication date |
---|---|
DE69131513T3 (de) | 2005-05-25 |
EP0449116A1 (en) | 1991-10-02 |
ES2140380T5 (es) | 2005-03-16 |
DE69131513T2 (de) | 2000-05-04 |
ATE183235T1 (de) | 1999-08-15 |
GR3031817T3 (en) | 2000-02-29 |
DE69131513D1 (de) | 1999-09-16 |
EP0449116B2 (en) | 2004-08-25 |
EP0449116B1 (en) | 1999-08-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2140380T3 (es) | Secuencias de adn que codifican polipeptidos gag retroviricos modificados y vacunas que las contienen o agregados de las mismas. | |
NO921969L (no) | Ikke-replikerende rekombinant fremstilte retroviruspartikler brukt som antivirale midler og immunogener | |
DK33190D0 (da) | Hiv-3 retrovirus og anvendelse heraf | |
ES2099066T3 (es) | Antigenos a partir de adn sintetico derivado del virus de la inmunodeficiencia humana (hiv-1). | |
JPH11322792A (ja) | ヒト免疫不全レトロウイルス(ウイルスhiv)に対して誘導された抗体により認識できるペプチド、及び前記ウイルスの或る種に起因する感染の診断、場合によってはエイズに対するワクチン接種における該ペプチドの使用。 | |
AP368A (en) | Derivatives of gp160 and vaccine based on gp160 or a derivative thereof, containing an adjuvant. | |
HUP0002176A2 (hu) | Vakcinákban vagy diagnosztikai vizsgálatokban alkalmazható PRRSV-peptidszekvenciákat azonosító PRRSV-antigénhelyek | |
ATE154610T1 (de) | Synthetische vom hiv-gp120-env-protein abgeleitete peptide und ihre anwendung | |
WO1989002277A2 (en) | Prophylaxis and therapy of acquired immunodeficiency syndrome | |
AR032871A1 (es) | Poxvirus recombinantes para proteinas quimericas del virus de la inmunodeficiencia humana | |
FI885296A0 (fi) | Rekombinant hiv-2 polypeptid. | |
BR9204851A (pt) | Antigeno de HIV e processo para sua produçao molécula de DNA recombinante, reagente para diagnóstico e vacina para sindrome da imunodeficiência adquirida | |
AU654970B2 (en) | Derivatives of gp160 and vaccines based on gp160 or a derivative thereof, containing an adjuvant | |
US5876724A (en) | Induction of neutralizing antibody against viral infection by synergy between virus envelope glycoprotein and peptides corresponding to neutralization epitopes of the glycoprotein | |
EP0472706B1 (en) | Induction of protection against viral infection | |
Saitoh et al. | A unique monoclonal antibody that recognizes mature p17 of HIV-1 but not its precursor | |
MY104530A (en) | Nonreplicating recombinant-made retroviral particles useful as anti-viral agents and as immunogens for pro- phylaxis and therapy against human retroviruses. | |
Girard et al. | Candidate vaccines for HIV | |
TH9629EX (th) | โพรเทเอส, รีเวอร์ส แทรนส์คริพเทส และเอนโดนิวคลี เอสของ ของเรโทรไวรัส และวิธีการสำหรับผลิตเอนไซม์เหล่า นี้ | |
TH13136EX (th) | แอนติเจนของ hiv | |
DE3709449A1 (de) | Herstellung traeger-gebundener synthetischer peptide zur verwendung als antigen in diagnostischen testen und zur erzeugung spezifischer immunantwort | |
FR2730243A1 (fr) | Polypeptides de glycoproteine trasmembranaire d'enveloppe du retrovirus humain du type hiv-1 et polypeptides presentant avec eux une parente immunologique |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG2A | Definitive protection |
Ref document number: 449116 Country of ref document: ES |